Nashville, TN, United States of America

Jeffrey A Clanton



Average Co-Inventor Count = 3.3

ph-index = 2

Forward Citations = 126(Granted Patents)


Company Filing History:


Years Active: 1986-1996

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Jeffrey A. Clanton

Introduction

Jeffrey A. Clanton is a notable inventor based in Nashville, TN (US). He has made significant contributions to the field of nuclear medicine through his innovative work on radioiodinated benzamines. With a total of 3 patents, Clanton's inventions are paving the way for advancements in medical imaging.

Latest Patents

Clanton's latest patents focus on the development of novel, substituted benzamides in radioiodinated form. These compounds are essential in radiopharmaceutical compositions used in nuclear medicine. They serve as imaging agents to detect, visualize, and analyze the distribution and function of the dopamine D2 receptor in the mammalian brain. The specific combination of lipophilicity and dopamine D2 receptor affinity in these compounds is crucial for achieving the required image contrast. The iodinated benzamides can be synthesized by reacting a trialkyltin substituted benzamide with an acid in the presence of radioactive iodine, which is generated by in situ oxidation of an appropriate iodide nuclide salt.

Career Highlights

Clanton is affiliated with Vanderbilt University, where he continues to contribute to research and innovation in his field. His work has garnered attention for its potential applications in improving diagnostic imaging techniques.

Collaborations

Some of Clanton's notable coworkers include Tomas De Paulis and Robert M. Kessler. Their collaborative efforts enhance the research environment and foster innovation in the field of nuclear medicine.

Conclusion

Jeffrey A. Clanton's contributions to the field of nuclear medicine through his innovative patents are noteworthy. His work not only advances medical imaging but also opens new avenues for research and development in radiopharmaceuticals.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…